No. Our two primary S1 agonists were not developed by "Anavex chemists" but by two different outside developers (we are licensees), and they are by no means the only two magically possible molecules for agonizing S1 safely and therapeutically. These "definitive" claims are definitively nonsense. There can be 1 other molecule, or 1,000 others.
And we don't even know if 3-71 is efficacious in human disease yet, so any proclamations about that molecule's unique effectiveness are false from the very start.
Also, the White Swan Fallacy that because you don't see a non-white swan that means they don't exist, that's nonsense, really poor reasoning, and fundamentally unscientific. Most folks trained in basic science know that, I suspect. (Btw we know of one non-white swan, a small company in clinical trials with a new S1 agonist for a CNS indication.)
FXS is a particularly exciting indication for us to pursue given its pathogenesis (effectively gene silencing) and the results with those KO models, which are pretty darn true to the actual condition (in mice). Looking forward to our clinical trial!